Mga Batayang Estadistika
| LEI | 54930028YG89VTY2J114 |
| CIK | 1743881 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BridgeBio Pharma, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio |
|
| August 5, 2025 |
Exhibit 10.2 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO FUNDING AGREEMENT This FIRST AMENDMENT TO FUNDING AGREEMENT (this “Amendment”), dated as of June 27, 2025 is made and entered into by and among (i) HEDGEWIG FUNDING I LP, a |
|
| August 5, 2025 |
Calculation of Filing Fee Tables BridgeBio Pharma, Inc. Exhibit 107 Calculation of Filing Fee Tables S-8 BridgeBio Pharma, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share, 2021 Amended and Restated Stock Option and Incentive Pla |
|
| August 5, 2025 |
As filed with the U.S. Securities and Exchange Commission on August 5, 2025 As filed with the U.S. Securities and Exchange Commission on August 5, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIDGEBIO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 84-1850815 (State or other jurisdiction of incorporation or organization) (I.R |
|
| August 5, 2025 |
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates Exhibit 99.1 BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates - As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - $110.6 million in total second quarter revenue, comprised of $71.5 million of |
|
| August 5, 2025 |
Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ROYALTY INTEREST PURCHASE AND SALE AGREEMENT by and among EIDOS THERAPEUTICS, INC., as the Company and BRIDGEBIO PHARMA, INC., as the Parent, on the one hand and ACORAMIDIS ROYALTY SPV, LP and |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 23, 2025 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BRIDGEBIO PHARMA, INC. BridgeBio Pharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: 1. That the Board of Directors of the Corporation has duly adopted resolutions pursuant |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 (June 20, 2025) BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation |
|
| June 23, 2025 |
Exhibit 10.1 BRIDGEBIO PHARMA, INC. SECOND AMENDED AND RESTATED 2021 STOCK OPTION AND INCENTIVE PLAN Section 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BridgeBio Pharma, Inc. Second Amended and Restated 2021 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 30, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio |
|
| April 29, 2025 |
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates Exhibit 99.1 BridgeBio Reports First Quarter 2025 Financial Results and Business Updates - $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for hypochondroplasia Phase 2 trial fully enrolled significantly ahead of schedule. The first participant was al |
|
| April 29, 2025 |
Consulting Agreement, dated March 17, 2025, between BridgeBio Pharma, Inc. and Brian Stephenson. Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is effective as of March 17, 2025, (the “Effective Date”), and is made by and between Brian Stephenson (“Consultant”), an individual |
|
| April 16, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| March 17, 2025 |
BridgeBio Announces CFO Succession Exhibit 99.1 BridgeBio Announces CFO Succession PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer (CFO) of the Company. He recently assumed the role of Principal |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 (March 17, 2025) BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporati |
|
| February 28, 2025 |
Exhibit 4.1 Execution BRIDGEBIO PHARMA, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of February 28, 2025 1.75% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 References to Interest 14 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES 14 Section 2.01 Designat |
|
| February 28, 2025 |
Exhibit 99.2 BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt - Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturity - Offering priced at 1.75% interest rate and 45% conversion premium PALO ALTO, Calif. – February 25, 2025 – BridgeBio Pharma, Inc. (Nasd |
|
| February 28, 2025 |
Exhibit 99.1 BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt - Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends deb |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 20, 2025 |
Employment Agreement between BridgeBio Services, Inc. and Thomas Trimarchi, dated October 10, 2024. Exhibit 10.42 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. October 9, 2024 Thomas Trimarchi Sent Via Email Re: BridgeBio Services, Inc. Employment Dear Tom: Consistent with your recent appointment as President and Chief Operating Officer of BridgeBio |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38959 BridgeBio Pharma, |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 20, 2025 |
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update Exhibit 99.1 BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - As of February 17, 2025, 1,028 unique patient prescriptions for AttrubyTM have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascu |
|
| February 20, 2025 |
List of Subsidiaries of the Registrant. Exhibit 21 List of Subsidiaries Entity Name Place of Incorporation Ownership % as of December 31, 2024 BB Square Capital Investors I, LP Delaware 100. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 13, 2025 |
Exhibit 99.2 J.P. Morgan Presentation January 13, 2025 Forward Looking Statements and Disclaimer The presentation contains forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, |
|
| January 13, 2025 |
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones Exhibit 99.1 BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types - Fully enrolled three major market Phase 3 clinical trials: FORTIFY (BBP-418 for LGMD2I/R9); CALIBRATE (encaleret for ADH1); and P |
|
| November 25, 2024 |
Exhibit 99.1 Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients - Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vita |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 12, 2024 |
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update Exhibit 99.1 BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update - Patients on acoramidis, a near complete (≥90%) TTR stabilizer in clinical development, lived longer and better as shown in the ATTRibute-CM study. This is the only Phase 3 study of an ATTR-CM disease-modifying treatment to demonstrate improvement in hard clinical outcomes in the combined assessment of |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 Bridg |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 6, 2024 |
BBIO / BridgeBio Pharma, Inc. / VIKING GLOBAL INVESTORS LP Activist Investment SC 13D/A 1 bbio.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4)* BridgeBio Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 10806X102 (CUSIP Number) Matthew Bloom General Counsel and Chief Compliance Officer 600 Washington Boulevard, Floor 11 Stamford, Connecticut 06901 (212) 672-7059 (N |
|
| September 17, 2024 |
BBIO / BridgeBio Pharma, Inc. / KKR Genetic Disorder L.P. - SC 13D/A Activist Investment SC 13D/A 1 ef20035948sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* BridgeBio Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 10806X102 (CUSIP Number) Christopher Lee, Esq. Kohlberg Kravis Roberts & Co. L.P. 30 Hudson Yards New |
|
| September 17, 2024 |
EX-99.1 2 ef20035948ex99-1.htm EXHIBIT I Exhibit I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of shares of Common Stock, $0.001 par value per share, of BridgeBio Pharma, Inc. is being filed, and all |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 11, 2024 |
Exhibit 99.1 BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) - Increase in endogenous cortisol production achieved in all patients in higher dose cohorts of BBP-631, a result seen for the first time ever in CAH patients - The gene therapy was well tolerated with no treatment-related serious adverse events (SAEs) |
|
| August 21, 2024 |
Exhibit 10.2 EXECUTION VERSION AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF BRIDGEBIOX PHARMA, LLC, a Delaware Limited Liability Company Dated as of August 16, 2024 Page ARTICLE I DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretive Provisions 18 ARTICLE II THE LIMITED LIABILITY COMPANY 19 2.1 Formation 19 2.2 Name 19 2.3 Business Purpose 19 2.4 Registered Office and Agent 19 2.5 Term 1 |
|
| August 21, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2024 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38959 (Commission File Number |
|
| August 21, 2024 |
Exhibit 10.1 EXECUTION VERSION TRANSACTION AGREEMENT dated as of August 16, 2024 by and among BRIDGEBIO PHARMA, INC., VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, PATIENT SQUARE BRAVO AGGREGATOR, LP, SC US/E GROWTH FUND X MANAGEMENT, L.P., SC US/E VENTURE FUND XVIII MANAGEMENT, L.P., FRAZIER LIFE SCIENCES XI, L.P., FRAZIER LI |
|
| August 20, 2024 |
BBIO / BridgeBio Pharma, Inc. / VIKING GLOBAL INVESTORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3)* BridgeBio Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 10806X102 (CUSIP Number) Andrew Genser General Counsel 600 Washington Boulevard, Floor 11 Stamford, Connecticut 06901 (212) 672-7050 (Name, Address and Telephone Number of Person Autho |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio |
|
| August 1, 2024 |
Execution Version CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| August 1, 2024 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 BridgeBio Pharma, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share, 2021 Amended and Restated Stock Option and Incentive Plan Other 6,50 |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 1, 2024 |
As filed with the U.S. Securities and Exchange Commission on August 1, 2024 As filed with the U.S. Securities and Exchange Commission on August 1, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIDGEBIO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 84-1850815 (State or other jurisdiction of incorporation or organization) (I.R |
|
| August 1, 2024 |
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update Exhibit 99.1 BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update - Acoramidis demonstrated a significant impact on mortality, hospitalizations, and quality of life - Starting at Month 3, patients taking acoramidis showed meaningful and sustained improvement in time to first event (CVH or ACM) - Acoramidis demonstrated a 42% reduction in composite CVH and ACM events r |
|
| August 1, 2024 |
Exhibit 10.2 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non- Employee Directors and Consultants of BridgeBio Ph |
|
| July 23, 2024 |
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer Exhibit 99.1 BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating O |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 24, 2024 |
2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Exhibit 10.1 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non- Employee Directors and Consultants of BridgeBio Ph |
|
| June 24, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 (June 21, 2024) BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation |
|
| June 6, 2024 |
Exhibit 99.1 BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia - In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2 |
|
| June 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 2, 2024 |
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. |
|
| May 2, 2024 |
Exhibit 99.1 BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update - Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed |
|
| May 2, 2024 |
Exhibit 10.4 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FUNDING AGREEMENT This FUNDING AGREEMENT (this “Agreement”), dated as of January 17, 2024 (the “Effective Date”), is made and entered into by and among (i) LSI FINANCING 1 DESIGNATED ACTIVITY |
|
| May 2, 2024 |
Exhibit 10.3 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO FINANCING AGREEMENT This FIRST AMENDMENT TO FINANCING AGREEMENT (this “Amendment”), dated as of February 12, 2024, is entered into by and among BRIDGEBIO PHARMA, INC., a Del |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 2, 2024 |
Exhibit 10.2 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FINANCING AGREEMENT dated as of January 17, 2024 among BRIDGEBIO PHARMA, INC., as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER FROM TIME TO TIME PARTY HERETO, as Guarantors, VARIOUS LEND |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio |
|
| May 2, 2024 |
Exclusive License Agreement, dated March 1, 2024, by and among Eidos Therapeutics, Inc., BridgeBio Exhibit 10.5 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT by and among Eidos Therapeutics, Inc., BridgeBio International GmbH, BridgeBio Europe B.V., and Bayer Consumer Care AG entered into as of March 1st, 2024 TABLE OF C |
|
| May 2, 2024 |
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 25, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| March 6, 2024 |
BridgeBio Pharma Announces Proposed Public Offering of Common Stock Exhibit 99.1 BridgeBio Pharma Announces Proposed Public Offering of Common Stock PALO ALTO, Calif. – March 4, 2024 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares of its common stock. BridgeBio also intends to g |
|
| March 6, 2024 |
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock Exhibit 99.2 BridgeBio Pharma Announces Pricing of Public Offering of Common Stock PALO ALTO, Calif. – March 5, 2024 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering p |
|
| March 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) BridgeBio Pharma, Inc. |
|
| March 6, 2024 |
Exhibit 1.1 CERTAIN IDENTIFIED INFORMATION, MARKED BY “[***]”, HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share Underwriting Agreement March 5, 2024 J.P. Morgan Securities LLC Cantor Fitzgerald & Co. Mizuho Securities USA LLC As representatives ( |
|
| March 6, 2024 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-271650 PROSPECTUS SUPPLEMENT (to Prospectus dated May 4, 2023) 8,620,690 Shares BridgeBio Pharma, Inc. Common Stock We are offering 8,620,690 shares of our common stock, par value $0.001 per share (the “common stock”). Our common stock is listed on The Nasdaq Global Select Market under the symbol “BBIO.” On March 4, 2024, |
|
| March 6, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 (March 5, 2024) BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 4, 2024 |
SUBJECT TO COMPLETION, DATED MARCH 4, 2024 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 22, 2024 |
Exhibit 10.39 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. February 21, 2024 Brian Stephenson Re: Amendment to Employment Agreement Dear Brian: This letter (this “Amendment”) confirms the agreement between you and BridgeBio Services, Inc. (the “Compa |
|
| February 22, 2024 |
Amended and Restated Insider Trading Policy. Exhibit 19 BRIDGEBIO PHARMA, INC. AMENDED AND RESTATED Insider Trading POLICY BridgeBio Pharma, Inc. (the “Company”) has adopted the following policy and procedures for securities trading by Company directors and employees (our “Insider Trading Policy”). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, and the severe con |
|
| February 22, 2024 |
Exhibit 97 BridgeBio Pharma, Inc. COMPENSATION CLAWBACK POLICY Adopted as of September 27, 2023 BridgeBio Pharma, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Clawback Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company may recover Erroneously Awarded Compensation (as defined below) from C |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38959 BridgeBio Pharma, |
|
| February 22, 2024 |
Exhibit 99.1 BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update - Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on positive results of Phase 3 ATTRibute-CM trial, which were published in the New England Journal of Medicine; NDA has b |
|
| February 22, 2024 |
List of Subsidiaries of the Registrant. Exhibit 21 List of Subsidiaries Entity Name Place of Incorporation Ownership % as of December 31, 2023 BB Square Capital Investors I, LP Delaware 100. |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 22, 2024 |
Exhibit 10.31 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. May 4, 2018 Novartis International Pharmaceutical Ltd. Lichtstrasse 35 CH-4056 Basel Switzerland RE: Letter Agreement relating to pharmacokinetic analysis and transfer or BGJ398 Material and |
|
| February 16, 2024 |
BBIO / BridgeBio Pharma, Inc. / Kumar Neil - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)* BridgeBio Pharma, Inc. (Name of issuer) Common Stock, par value $0.001 per share (Title of class of securities) 10806X 102 (CUSIP number) 12/31/2023 (D |
|
| February 13, 2024 |
BBIO / BridgeBio Pharma, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Bridgebio Pharma Inc Title of Class of Securities: Common Stock CUSIP Number: 10806X102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 8, 2024 |
Exhibit 99.1 JPM Presentation 2024 Forward-Looking Statement and Disclaimer The presentation may contain forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 5, 2024 |
BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan. Exhibit 99.1 BRIDGEBIO PHARMA, INC. AMENDED AND RESTATED 2019 INDUCEMENT EQUITY PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (formerly known as the BridgeBio Pharma, Inc. 2019 Inducement Equity Plan) (the “Plan”). The purpose of the Plan is to enable BridgeBio Pharma, Inc., a Delaware co |
|
| January 5, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) BridgeBio Pharma, Inc. |
|
| January 5, 2024 |
As filed with the U.S. Securities and Exchange Commission on January 5, 2024 As filed with the U.S. Securities and Exchange Commission on January 5, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIDGEBIO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 84-1850815 (State or other jurisdiction of incorporation or organization) (I. |
|
| November 22, 2023 |
BBIO / BridgeBio Pharma Inc / VIKING GLOBAL INVESTORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2)* BridgeBio Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 10806X102 (CUSIP Number) Andrew Genser General Counsel 55 Railroad Avenue Greenwich, Connecticut 06830 (212) 672-7050** (Name, Address and Telephone Number of Person Authorized to Rece |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 Bridg |
|
| November 2, 2023 |
As filed with the Securities and Exchange Commission on November 2, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 2, 2023 Registration No. |
|
| November 2, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3ASR (Form Type) BridgeBio Pharma, Inc. |
|
| November 2, 2023 |
Exhibit 99.1 BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update - Presented detailed positive results from the ATTRibute-CM Phase 3 study of acoramidis at the European Society of Cardiology (ESC) Congress, demonstrating that patients survived more and were hospitalized less than has been seen in other interventional studies of transthyretin amyloid cardiomyopathy (AT |
|
| November 2, 2023 |
[***] Certain information in this exhibit has been omitted because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 25, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 25, 2023, by and between BridgeBio Pharma, Inc., a Delaware corporation (the “Company”), and each of the several purchasers identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, the Compa |
|
| September 25, 2023 |
Exhibit 99.1 BridgeBio Pharma Announces $250 Million Private Placement Equity Financing - $250 million financing led by Qatar Investment Authority (QIA) with significant participation from four of the largest investment management firms in the US - BridgeBio anticipates this raise, coupled with several less dilutive financings available to the Company, fully capitalizes the Company to profitabilit |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 25, 2023 |
[***] Certain information in this exhibit has been omitted because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| August 3, 2023 |
Exhibit 10.8 NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ 1 Grant Date: Expiration Date: 2 1 Note to Form: FMV on Grant Date 2 Note to Form: No more than 10 years Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option a |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio |
|
| August 3, 2023 |
Exhibit 10.3 RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE BRIDGEBIO PHARMA, INC. AMENDED AND RESTATED 2019 INDUCEMENT EQUITY PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan as amended through the date hereof (the “Plan”), BridgeBio Pharma, Inc. (the “Company”) hereby grants an award of the n |
|
| August 3, 2023 |
Exhibit 99.1 BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update - Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 (p<0.0001) and clinically meaningful a |
|
| August 3, 2023 |
Exhibit 10.5 NON-QUALIFIED STOCK OPTION AGREEMENT UNDER BRIDGEBIO PHARMA, INC. AMENDED AND RESTATED 2019 INDUCEMENT EQUITY PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ 1 Grant Date: Expiration Date: 2 1 Note to Form: FMV on Grant Date 2 Note to Form: No more than 10 years Pursuant to the BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan as a |
|
| August 3, 2023 |
Exhibit 10.6 RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), BridgeBio Pharma, Inc. (the “Company”) hereby grants |
|
| August 3, 2023 |
Exhibit 10.7 RESTRICTED STOCK AWARD AGREEMENT UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Shares: Grant Date: Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (the “Plan”) as amended through the date hereof, BridgeBio Pharma, Inc. (the “Company”) hereby grants a Restricted Stock A |
|
| August 3, 2023 |
Exhibit 10.9 NON-QUALIFIED STOCK OPTION AGREEMENT FOR DIRECTORS UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ 1 Grant Date: Expiration Date: 2 1 Note to Form: FMV on Grant Date 2 Note to Form: No more than 10 years Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. |
|
| August 3, 2023 |
Exhibit 10.4 RESTRICTED STOCK AWARD AGREEMENT UNDER THE BridgeBio Pharma, INC. AMENDED AND RESTATED 2019 INDUCEMENT EQUITY PLAN Name of Grantee: No. of Shares: Grant Date: Pursuant to the BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (the “Plan”) as amended through the date hereof, BridgeBio Pharma, Inc. (the “Company”) hereby grants a Restricted Stock Award (an “Award”) |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 26, 2023 |
As filed with the Securities and Exchange Commission on July 26, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 26, 2023 Registration No. |
|
| July 26, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BridgeBio Pharma, Inc. |
|
| July 20, 2023 |
EXHIBIT 99.4 JOINT FILING AGREEMENT This joint filing agreement is made and entered into as of this 19th day of July, 2023, by and among VIKING GLOBAL INVESTORS LP, VIKING GLOBAL PERFORMANCE LLC, VIKING GLOBAL EQUITIES MASTER LTD., VIKING LONG FUND GP LLC, VIKING LONG FUND MASTER LTD., VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFO |
|
| July 20, 2023 |
BBIO / BridgeBio Pharma Inc / VIKING GLOBAL INVESTORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* BridgeBio Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 10806X102 (CUSIP Number) Andrew Genser General Counsel 55 Railroad Avenue Greenwich, Connecticut 06830 203-863-7050 (Name, Address and Telephone Number of Person Authorized to Receive |
|
| July 17, 2023 |
Exhibit 99.2 ATTRibute-CM Phase 3 Topline Results July 17, 2023 1 Forward-Looking Statements and Disclaimer 2 The presentation at the call may contain forward-looking statements. Statements made or presented at the call may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 17, 2023 |
Exhibit 99.1 BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) – Highly statistically significant result observed on primary endpoint with a Win Ratio of 1.8 (p<0.0001) – 58% of ties in Finkelstein-Schoenfeld (F-S) primary analysis broken by all-cause mortality and frequency of cardiovasc |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 4, 2023 |
Exhibit 1.2 EQUITY DISTRIBUTION AGREEMENT May 4, 2023 GOLDMAN SACHS & CO. LLC 200 West Street New York, New York 10282 SVB SECURITIES LLC 1301 6th Avenue, 12th Floor New York, New York 10019 Ladies and Gentlemen: BridgeBio Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Goldman Sachs & Co |
|
| May 4, 2023 |
Power of Attorney (included in the signature pages to this registration statement). S-3ASR 1 d369975ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1850815 (State or other jurisdi |
|
| May 4, 2023 |
Form of indenture for senior debt securities and the related form of senior debt security. EX-4.4 Exhibit 4.4 BRIDGEBIO PHARMA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section |
|
| May 4, 2023 |
EX-4.5 Exhibit 4.5 BRIDGEBIO PHARMA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Tru |
|
| May 4, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) BridgeBio Pharma, Inc. |
|
| May 4, 2023 |
Exhibit 10.4 BRIDGEBIO PHARMA, INC. AMENDED AND RESTATED 2019 INDUCEMENT EQUITY PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (formerly known as the BridgeBio Pharma, Inc. 2019 Inducement Equity Plan) (the “Plan”). The purpose of the Plan is to enable BridgeBio Pharma, Inc., a Delaware co |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio |
|
| May 4, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BridgeBio Pharma, Inc. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission File |
|
| May 4, 2023 |
Power of Attorney (included on signature page) S-8 As filed with the U.S. Securities and Exchange Commission on May 4, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIDGEBIO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 84-1850815 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission File |
|
| May 4, 2023 |
EX-99.1 Exhibit 99.1 BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update - Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit and remains on track for topline month 30 registrational data to be announced in late July 2023 - Positive results announced in Cohort 5 of Phase |
|
| April 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 9, 2023 |
BridgeBio Pharma Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 BridgeBio Pharma Announces Proposed Public Offering of Common Stock PALO ALTO, CA – March 6, 2023 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $150 million of shares of its common stock. BridgeBio also intends |
|
| March 9, 2023 |
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock EX-99.2 5 d463641dex992.htm EX-99.2 Exhibit 99.2 BridgeBio Pharma Announces Pricing of Public Offering of Common Stock PALO ALTO, CA – March 8, 2023 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 7, 2023 of an underwritten public offering of 8,823,530 shares of its com |
|
| March 9, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) BridgeBio Pharma, Inc. |
|
| March 9, 2023 |
8,823,530 Shares BridgeBio Pharma, Inc. Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-239734 PROSPECTUS SUPPLEMENT (to Prospectus dated July 7, 2020) 8,823,530 Shares BridgeBio Pharma, Inc. Common Stock We are offering 8,823,530 shares of our common stock, par value $0.001 per share (the “common stock”). Our common stock is listed on The Nasdaq Global Select Market under the symbol “BBIO.” On March 7, 202 |
|
| March 9, 2023 |
EX-1.1 Exhibit 1.1 CERTAIN IDENTIFIED INFORMATION, MARKED BY “[***]”, HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share Underwriting Agreement March 7, 2023 Goldman Sachs & Co. LLC Evercore Group L.L.C. Morgan Stanley & Co. LLC A |
|
| March 9, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 6, 2023 |
SUBJECT TO COMPLETION, DATED MARCH 6, 2023 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-239734 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| March 6, 2023 |
EX-99.1 Exhibit 99.1 BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events - In the highest dose level (Cohort 5, 0.25 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) at six months was +3.03 cm/yr (p = 0.0022) for |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):March 6, 2023 BridgeBio Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 6, 2023 |
EX-99.2 PROPEL2 topline results March 6th, 2023 Exhibit 99.2 Forward-looking statements This presentation contains forward-looking statements. Statements in this presentation may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Excha |
|
| February 23, 2023 |
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. |
|
| February 23, 2023 |
Consulting Agreement between Frank McCormick and the Registrant, effective as of January 1, 2021. [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38959 BridgeBio Pharma, |
|
| February 23, 2023 |
Exhibit 10.33 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT is made and dated as of November 30, 2022 (this “Second Amendment”) by and among BRIDGEBIO PHARMA, INC., a Delaware corporation (“Borrower”), each other Person party hereto as a guarantor (each a “Guarantor” and collectively, the “Guarantors”), the several banks and other financial in |
|
| February 23, 2023 |
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. |
|
| February 23, 2023 |
EX-99.1 Exhibit 99.1 BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update –Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected to be announced in mid-2023 –Phase 2 PROPEL 2 trial of low-dose infigratinib as a |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commissio |
|
| February 23, 2023 |
List of Subsidiaries of the Registrant. Exhibit 21 List of Subsidiaries Entity Name Place of Incorporation Ownership % as of December 31, 2022 BB Square Capital Investors I, LP Delaware 100. |
|
| February 14, 2023 |
BBIO / BridgeBio Pharma Inc / Kumar Neil - SC 13G/A Passive Investment SC 13G/A 1 d440657dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)* BridgeBio Pharma, Inc. (Name of issuer) Common Stock, par value $0.001 per share (Title of class of securities) |
|
| February 9, 2023 |
BBIO / BridgeBio Pharma Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Bridgebio Pharma Inc. Title of Class of Securities: Common Stock CUSIP Number: 10806X102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 6, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) BridgeBio Pharma, Inc. |
|
| February 6, 2023 |
As filed with the U.S. Securities and Exchange Commission on February 6, 2023 S-8 As filed with the U.S. Securities and Exchange Commission on February 6, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIDGEBIO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 84-1850815 (State or other jurisdiction of incorporation or organization |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commissio |
|
| November 3, 2022 |
Exhibit 99.1 BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update - Reported positive preclinical data for its next-generation KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3K?:RAS breaker mechanism in late lead optimization - Reported positive updated 12-month Phase 2 data for BBP-418 in Limb-Girdle Muscular Dystrophy Type |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio Pharma, Inc. |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission |
|
| September 23, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commissi |
|
| August 4, 2022 |
Exhibit 99.1 BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update - Reported positive interim Phase 2 data for infigratinib in achondroplasia demonstrating a mean increase in annualized height velocity (AHV) of 1.52 cm/year among all Cohort 4 children 5 years of age and older, and announced addition of a 5th cohort to the trial - Reported positive Phase 2 data f |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio Pharma, Inc. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission F |
|
| August 4, 2022 |
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. |
|
| August 4, 2022 |
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. |
|
| July 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 24, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 18, 2022 |
Exhibit 99.1 BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years -Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110 million -Secured a two-year extension of interest-only period on its existing senior secured credit fac |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 13, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 13, 2022 |
Exhibit 99.1 BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology - BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties -SHP2 inhibitor deal expands earlier agreement be |
|
| May 10, 2022 |
Exhibit 99.1 BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update ? Completed sale to Sentynl Therapeutics of BridgeBio?s NULIBRY? (Fosdenopterin) for Injection ? Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib in oncology indications in the U.S.; BridgeBio is eligible to receive regulatory and commercial milest |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission File |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio Pharma, Inc. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| February 25, 2022 |
List of Subsidiaries of the Registrant. Exhibit 21 List of Subsidiaries Entity Name Place of Incorporation Ownership % as of December 31, 2021 BridgeBio Pharma LLC Delaware 100. |
|
| February 25, 2022 |
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. |
|
| February 25, 2022 |
As filed with the U.S. Securities and Exchange Commission on February 25, 2022 As filed with the U.S. Securities and Exchange Commission on February 25, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIDGEBIO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 84-1850815 (State or other jurisdiction of incorporation or organization) ( |
|
| February 25, 2022 |
Amended and Restated 2021 Stock Option and Incentive Plan and forms of award agreements thereunder. Exhibit 10.1 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of BridgeBio Pha |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38959 BridgeBio Pharma, |
|
| February 25, 2022 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK OF BRIDGEBIO PHARMA, INC. The following description of the capital stock of BridgeBio Pharma, Inc. (the ?Company?, ?we?, ?us? and ?our?) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation (the ?certificate of incorporation?) and our amended an |
|
| February 25, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) BridgeBio Pharma, Inc. |
|
| February 25, 2022 |
Amended and Restated Director Compensation Policy. Exhibit 10.30 BridgeBio Pharma, Inc. Amended and Restated Director Compensation Policy The purpose of this Amended and Restated Director Compensation Policy (this ?Policy?) of BridgeBio Pharma, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract, retain and motivate on a long-term basis, high-caliber directors and the type of |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commissio |
|
| February 24, 2022 |
Exhibit 99.1 BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update ?Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio?s financial runway into 2024 ?Dosed first patient in Phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (CAH); initial data readout anticipated in second half of |
|
| February 15, 2022 |
BBIO / BridgeBio Pharma Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* BridgeBio Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 10806X 102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 15, 2022 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2022 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2022 |
BBIO / BridgeBio Pharma Inc / Kumar Neil - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)* BridgeBio Pharma, Inc. (Name of issuer) Common Stock, par value $0.001 per share (Title of class of securities) 10806X 102 (CUSIP number) 12/3 |
|
| February 9, 2022 |
BBIO / BridgeBio Pharma Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Bridgebio Pharma Inc. Title of Class of Securities: Common Stock CUSIP Number: 10806X102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| December 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commissio |
|
| December 27, 2021 |
BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study Exhibit 99.1 BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study ? ATTRibute-CM did not meet its primary endpoint at Month 12. Mean observed six-minute walk distance (6MWD) decline for the acoramidis and placebo arms were 9 meters and 7 meters, respectively. Both declines are similar to healthy elderly adults and less than prior untreated ATTR-CM cohorts ? The company |
|
| December 16, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commissio |
|
| November 18, 2021 |
BridgeBio Pharma, Inc. Secures Up to $750 Million in Exhibit 99.1 BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing -Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Company?s 30+ genetic disease and cancer pipeline programs into 2024 -Together with approximately $385.6 million in share and capped call purchases executed since the C |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commissio |
|
| November 8, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio Pharma, Inc. |
|
| November 4, 2021 |
Exhibit 99.1 BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update ? Topline results from Part A of the Phase 3 ATTRibute-CM trial of TTR stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM) expected by end of 2021 ? Meaningful progress in RAS cancer portfolio with discovery of next-generation KRAS G12C dual inhibitors and novel PI3k?:RAS breakers ? Advancement |
|
| November 4, 2021 |
Amended and Restated 2019 Employee Stock Purchase Plan. Exhibit 10.1 BRIDGEBIO PHARMA, INC. AMENDED AND RESTATED 2019 EMPLOYEE STOCK PURCHASE PLAN The purpose of the BridgeBio Pharma, Inc. Amended and Restated 2019 Employee Stock Purchase Plan (?the Plan?) is to provide eligible employees of BridgeBio Pharma, Inc. (the ?Company?) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission |
|
| October 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| October 26, 2021 |
Exhibit 99.1 BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ ? BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: H |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission |
|
| August 24, 2021 |
Exhibit 99.1 BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors PALO ALTO, CA ? August 18, 2021 ? BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear gene |
|
| August 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission F |
|
| August 13, 2021 |
Exhibit 99.1 BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update ? Received U.S. Food and Drug Administration (FDA) approval for TRUSELTIQ? (infigratinib) under the accelerated approval program for patients with cholangiocarcinoma (CCA) ? Received FDA Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia (ADH1) ? Received FDA |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio Pharma, Inc. |
|
| June 22, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 1, 2021 |
Exhibit 99.1 Corporate presentation June 2021Exhibit 99.1 Corporate presentation June 2021 Forward-Looking Statements and Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-loo |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission File |
|
| May 14, 2021 |
Exhibit 99.1 BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update ?Received U.S. Food and Drug Administration (FDA) approval for NULIBRY? (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A ?Reported proof-of-concept data of encaleret in Autosomal Dominant Hypocalcemia Ty |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 6, 2021 |
Amended and Restated Employee Stock Purchase Plan Exhibit 10.4 BRIDGEBIO PHARMA, INC. AMENDED AND RESTATED 2019 EMPLOYEE STOCK PURCHASE PLAN The purpose of the BridgeBio Pharma, Inc. Amended and Restated 2019 Employee Stock Purchase Plan (?the Plan?) is to provide eligible employees of BridgeBio Pharma, Inc. (the ?Company?) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio Pharma, Inc. |
|
| May 6, 2021 |
Exhibit 10.3 SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of April 13, 2021, is entered into by and among BRIDGEBIO PHARMA, INC., a Delaware corporation (?New Parent?), BRIDGEBIO PHARMA LLC, a Delaware limited liability company (?Parent?), BRIDGEBIO SERVICES INC., a Delaware corporation (?Services Company?), SUB20, |
|
| April 30, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission F |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commission F |
|
| February 26, 2021 |
EX-99.1 2 d435408dex991.htm EX-99.1 Exhibit 99.1 BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update • Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos’ product candidate, acoramidis, |
|
| February 26, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incorporation) (Commissio |
|
| February 25, 2021 |
EX-4.3 2 bbio-ex43700.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK OF BRIDGEBIO PHARMA, INC. The following description of the capital stock of BridgeBio Pharma, Inc. (the “Company”, “we”, “us” and “our”) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation (the “certificate of i |
|
| February 25, 2021 |
List of Subsidiaries of the Registrant. EX-21 5 bbio-ex2119.htm EX-21 Exhibit 21 List of Subsidiaries Entity Name State of Incorporation BridgeBio Pharma LLC Delaware TheRas, Inc. Delaware BridgeBio Services Inc. Delaware Origin Biosciences, Inc. Delaware Fortify Therapeutics, Inc. Delaware Sub20, Inc. Delaware Eidos Therapeutics, Inc. Delaware Molecular Skin Therapeutics, Inc. Delaware Navire Pharma, Inc. Delaware CoA Therapeutics, Inc |
|
| February 25, 2021 |
Exhibit 10.40 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of March 2, 2020, is entered into by and among BRIDGEBIO PHARMA, INC., a Delaware corporation (?New Parent?), BRIDGEBIO PHARMA LLC, a Delaware limited liability company (?Parent?), BRIDGEBIO SERVICES INC., a Delaware corporation (?Services Company?), SUB20, |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38959 BridgeBio Pharma, |
|
| February 25, 2021 |
Exhibit 10.46 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of January 25, 2021, is entered into by and among BRIDGEBIO PHARMA, INC., a Delaware corporation (?New Parent?), BRIDGEBIO PHARMA LLC, a Delaware limited liability company (?Parent?), BRIDGEBIO SERVICES INC., a Delaware corporation (?Services Company?), SUB2 |
|
| February 17, 2021 |
bridgebio pharma, inc. announces pricing of secondary offering of common stock EX-99.2 5 d138536dex992.htm EX-99.2 Exhibit 99.2 bridgebio pharma, inc. announces pricing of secondary offering of common stock 12.02.2021 at 8:00 AM EST PALO ALTO, Calif. , Feb. 12, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of a secondary public offering of 3,000,000 shares of its common stock at a price per shar |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* BridgeBio Pharma Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 10806X102 (CUSIP Number) David J. Sorkin, Esq. Kohlberg Kravis Roberts & Co. L.P. 30 Hudson Yards New York, New York 10001 Telephone: (212) 750 |
|
| February 17, 2021 |
Exhibit 1.1 Execution Version BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share Underwriting Agreement February 11, 2021 Goldman Sachs & Co. LLC, As representative (the ?Representative?) of the several Underwriters named in Schedule I hereto, Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282. Ladies and Gentlemen: The stockholder named in Schedule II hereto (the ?Sel |
|
| February 17, 2021 |
bridgebio pharma, inc. announces launch of secondary offering of common stock EX-99.1 Exhibit 99.1 bridgebio pharma, inc. announces launch of secondary offering of common stock 11.02.2021 at 4:10 PM EST PALO ALTO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of 3,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P. T |
|
| February 17, 2021 |
Exhibit H BridgeBio Pharma, Inc. Lock-Up Agreement February 11, 2021 Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282. Re: BridgeBio Pharma, Inc. - Lock-Up Agreement Ladies and Gentlemen: The undersigned understands that you, as representative (the “Representative”), propose to enter into an Underwriting Agreement on behalf of the several Underwriters named in Schedule I to such |
|
| February 17, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 (February 11, 2021) BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of incor |
|
| February 16, 2021 |
EXHIBIT 99.1 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. American International Group, Inc. — Subsidiary Information AIG Capital Corporation: A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G) Category Symbol: HC AIG Global Asset Management Holdings Corp.: A parent holding compa |
|
| February 16, 2021 |
EX-99.2 3 tm216212d1ex99-2.htm EXHIBIT 99.2 EXHIBIT 99.2 AGREEMENT OF JOINT FILING In accordance with Rule 13d-1(k), promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing on behalf of each of them of a Statement on Schedule 13G, and any amendments thereto, with respect to the Common Stock of Macy’s, Inc. and that this Agreement |
|
| February 16, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240. |
|
| February 16, 2021 |
EX-1 2 d137070dex1.htm EX-1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERC |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)* BridgeBio Pharma, Inc. (Name of issuer) Common Stock, par value $0.001 per share (Title of class of securities) 10806X 102 (CUSIP number) 12/3 |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* BridgeBio Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 10806X 102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 16, 2021 |
3,000,000 Shares BridgeBio Pharma, Inc. Common Stock Table of Contents Filed pursuant to Rule 424(b)(7) Registration No. 333-240147 PROSPECTUS SUPPLEMENT (to Prospectus dated July 28, 2020) 3,000,000 Shares BridgeBio Pharma, Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 3,000,000 shares of our common stock, par value $0.001 per share (the ?common stock?). We are not selling any shares of common stock |
|
| February 11, 2021 |
SUBJECT TO COMPLETION, DATED FEBRUARY 11, 2021 424B7 Table of Contents Filed pursuant to Rule 424(b)(7) Registration No. 333-240147 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| February 10, 2021 |
SC 13G 1 tv0408-bridgebiopharmainc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Bridgebio Pharma Inc. Title of Class of Securities: Common Stock CUSIP Number: 10806X102 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant |
|
| January 29, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 (January 25, 2021) BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38959 84-1850815 (State or other jurisdiction of inc |
|
| January 29, 2021 |
EX-4.1 2 d116562dex41.htm EX-4.1 Exhibit 4.1 Execution Version BRIDGEBIO PHARMA, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of January 28, 2021 2.25% Convertible Senior Notes due 2029 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 References to Interest 14 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES |
|
| January 29, 2021 |
Form of Confirmation for Capped Call Transactions. EX-10.1 Exhibit 10.1 January [], 2021 From: [Dealer] [] [] [] To: BridgeBio Pharma, Inc. 421 Kipling Street Palo Alto, CA 94301 Attention: Chief Financial Officer Telephone: 650-391-9740 Re: [Base]1[Additional]2 Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [] (“Dealer”) |
